{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:19:26Z","timestamp":1777421966551,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004205","name":"Osaka Kidney Foundation","doi-asserted-by":"publisher","award":["OKF21-0003"],"award-info":[{"award-number":["OKF21-0003"]}],"id":[{"id":"10.13039\/501100004205","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Takeda Medical Foundation"},{"name":"JSPS KAKENHI","award":["22K08368"],"award-info":[{"award-number":["22K08368"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-alcoholic fatty liver disease is the most common chronic liver disease and is associated with chronic kidney disease. The fibrosis-4 index and non-alcoholic fatty liver disease score are widely used as non-invasive diagnostic methods for non-alcoholic fatty liver disease. However, the relationship between these markers and specific renal histopathologies in chronic kidney disease remain unclear. This study included 179 patients aged between 16 and 80\u00a0years who underwent renal biopsy. We examined the association between the fibrosis-4 index or non-alcoholic fatty liver disease score and change in estimated glomerular filtration rate 12\u00a0months after kidney biopsy for each renal histopathology. Renal histopathologies were determined by renal biopsy. Our results showed that there was a significant negative correlation between the fibrosis-4 index and estimated glomerular filtration rate. In nephrosclerosis, the non-alcoholic fatty liver disease score and estimated glomerular filtration rate tended to have a negative correlation, albeit without significance. In IgA nephropathy, both the fibrosis-4 index and non-alcoholic fatty liver disease score were significantly negatively correlated with estimated glomerular filtration rate. Furthermore, the fibrosis-4 index was not associated with urinary protein-to-creatinine ratio or renal function markers such as urinary b2 microglobulin and urinary <jats:italic>N<\/jats:italic>-acetyl-<jats:sc>d<\/jats:sc>-glucosamine. Our kidney biopsy-based study showed that the liver fibrosis markers fibrosis-4 index and non-alcoholic fatty liver disease score were negatively correlated with the estimated glomerular filtration rate in nephrosclerosis and IgA nephropathy.<\/jats:p>","DOI":"10.1038\/s41598-022-22636-9","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:03:36Z","timestamp":1666346616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prediction of decreased estimated glomerular filtration rate using liver fibrosis markers: a renal biopsy-based study"],"prefix":"10.1038","volume":"12","author":[{"given":"Akira","family":"Mima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"22636_CR1","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"C Diabetes","year":"1993","unstructured":"Diabetes, C. et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977\u2013986 (1993).","journal-title":"N. Engl. J. Med."},{"key":"22636_CR2","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1681\/ASN.2005111241","volume":"17","author":"HJ Kramer","year":"2006","unstructured":"Kramer, H. J. et al. Increasing body mass index and obesity in the incident ESRD population. J. Am. Soc. Nephrol. 17, 1453\u20131459 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"22636_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/ki.2010.526","volume":"79","author":"A Mima","year":"2011","unstructured":"Mima, A. et al. Glomerular-specific protein kinase C-beta-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity. Kidney Int. 79, 883\u2013896 (2011).","journal-title":"Kidney Int."},{"key":"22636_CR4","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1056\/NEJMra1715733","volume":"379","author":"D Fuster","year":"2018","unstructured":"Fuster, D. & Samet, J. H. Alcohol use in patients with chronic liver disease. N. Engl. J. Med. 379, 2579 (2018).","journal-title":"N. Engl. J. Med."},{"key":"22636_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1096\/fj.04-2291fje","volume":"19","author":"M Carmiel-Haggai","year":"2005","unstructured":"Carmiel-Haggai, M., Cederbaum, A. I. & Nieto, N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J. 19, 136\u2013138 (2005).","journal-title":"FASEB J."},{"key":"22636_CR6","doi-asserted-by":"publisher","first-page":"20240","DOI":"10.1038\/s41598-021-99400-y","volume":"11","author":"P Sorino","year":"2021","unstructured":"Sorino, P. et al. Development and validation of a neural network for NAFLD diagnosis. Sci. Rep. 11, 20240 (2021).","journal-title":"Sci. Rep."},{"key":"22636_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter, T. G. & Rinella, M. Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology 158, 1851\u20131864 (2020).","journal-title":"Gastroenterology"},{"key":"22636_CR8","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.1038\/s41598-020-65940-y","volume":"10","author":"YE Chon","year":"2020","unstructured":"Chon, Y. E. et al. Decrease in waist-to-hip ratio reduced the development of chronic kidney disease in non-obese non-alcoholic fatty liver disease. Sci. Rep. 10, 8996 (2020).","journal-title":"Sci. Rep."},{"key":"22636_CR9","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera, L., Friedrich-Rust, M. & Loomba, R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1264\u20131281 (2019).","journal-title":"Gastroenterology"},{"key":"22636_CR10","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s10157-020-02018-z","volume":"25","author":"M Hara","year":"2021","unstructured":"Hara, M. et al. Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: The Fukuoka Kidney disease Registry Study. Clin. Exp. Nephrol. 25, 822\u2013834 (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"22636_CR11","doi-asserted-by":"publisher","first-page":"11753","DOI":"10.1038\/s41598-021-88285-6","volume":"11","author":"H Saito","year":"2021","unstructured":"Saito, H. et al. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci. Rep. 11, 11753 (2021).","journal-title":"Sci. Rep."},{"key":"22636_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","volume":"117","author":"J Vieira Barbosa","year":"2022","unstructured":"Vieira Barbosa, J. et al. Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 117, 453\u2013461 (2022).","journal-title":"Am. J. Gastroenterol."},{"key":"22636_CR13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2021.12.004","volume":"76","author":"DA Fraser","year":"2021","unstructured":"Fraser, D. A. et al. A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. J. Hepatol. 76, 800\u2013811 (2021).","journal-title":"J. Hepatol."},{"key":"22636_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/248563","volume":"2013","author":"A Mima","year":"2013","unstructured":"Mima, A. Inflammation and oxidative stress in diabetic nephropathy: New insights on its inhibition as new therapeutic targets. J. Diabetes Res. 2013, 248563 (2013).","journal-title":"J. Diabetes Res."},{"key":"22636_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/2211-5463.12400","volume":"8","author":"A Mima","year":"2018","unstructured":"Mima, A., Yasuzawa, T., King, G. L. & Ueshima, S. Obesity-associated glomerular inflammation increases albuminuria without renal histological changes. FEBS Open Bio 8, 664\u2013670 (2018).","journal-title":"FEBS Open Bio"},{"key":"22636_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jdiacomp.2013.03.003","volume":"27","author":"A Mima","year":"2013","unstructured":"Mima, A. Diabetic nephropathy: Protective factors and a new therapeutic paradigm. J. Diabetes Compl. 27, 526\u2013530 (2013).","journal-title":"J. Diabetes Compl."},{"key":"22636_CR17","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2337\/db11-1824","volume":"61","author":"A Mima","year":"2012","unstructured":"Mima, A. et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 61, 2967\u20132979 (2012).","journal-title":"Diabetes"},{"key":"22636_CR18","volume":"27","author":"AA Dawood","year":"2021","unstructured":"Dawood, A. A., Saleh, A. A., Elbahr, O., Gohar, S. F. & Habieb, M. S. Inverse relationship between the level of miRNA 148a\u20133p and both TGF-beta1 and FIB-4 in hepatocellular carcinoma. Biochem. Biophys. Rep. 27, 101082 (2021).","journal-title":"Biochem. Biophys. Rep."},{"key":"22636_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017929","volume":"6","author":"A Mima","year":"2011","unstructured":"Mima, A. et al. Activation of Src mediates PDGF-induced Smad1 phosphorylation and contributes to the progression of glomerulosclerosis in glomerulonephritis. PLoS ONE 6, e17929 (2011).","journal-title":"PLoS ONE"},{"key":"22636_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000020595","volume":"7","author":"AB Fogo","year":"1999","unstructured":"Fogo, A. B. Mesangial matrix modulation and glomerulosclerosis. Exp. Nephrol. 7, 147\u2013159 (1999).","journal-title":"Exp. Nephrol."},{"key":"22636_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.aohep.2019.07.013","volume":"19","author":"S Kiapidou","year":"2020","unstructured":"Kiapidou, S., Liava, C., Kalogirou, M., Akriviadis, E. & Sinakos, E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know?. Ann. Hepatol. 19, 134\u2013144 (2020).","journal-title":"Ann. Hepatol."},{"key":"22636_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.semnephrol.2012.07.010","volume":"32","author":"A Mima","year":"2012","unstructured":"Mima, A., Qi, W. & King, G. L. Implications of treatment that target protective mechanisms against diabetic nephropathy. Semin. Nephrol. 32, 471\u2013478 (2012).","journal-title":"Semin. Nephrol."},{"key":"22636_CR23","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1503\/cmaj.045232","volume":"172","author":"LA Adams","year":"2005","unstructured":"Adams, L. A., Angulo, P. & Lindor, K. D. Nonalcoholic fatty liver disease. CMAJ 172, 899\u2013905 (2005).","journal-title":"CMAJ"},{"key":"22636_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7861\/clinmedicine.6-1-19","volume":"6","author":"CP Day","year":"2006","unstructured":"Day, C. P. Non-alcoholic fatty liver disease: Current concepts and management strategies. Clin. Med. (Lond) 6, 19\u201325 (2006).","journal-title":"Clin. Med. (Lond)"},{"key":"22636_CR25","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2337\/dc06-1539","volume":"30","author":"KG Tolman","year":"2007","unstructured":"Tolman, K. G., Fonseca, V., Dalpiaz, A. & Tan, M. H. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30, 734\u2013743 (2007).","journal-title":"Diabetes Care"},{"key":"22636_CR26","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4093\/dmj.2017.41.6.430","volume":"41","author":"E Han","year":"2017","unstructured":"Han, E. & Lee, Y. H. Non-alcoholic fatty liver disease: The emerging burden in cardiometabolic and renal diseases. Diabetes Metab. J. 41, 430\u2013437 (2017).","journal-title":"Diabetes Metab. J."},{"key":"22636_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ebiom.2019.04.036","volume":"43","author":"J Lambrecht","year":"2019","unstructured":"Lambrecht, J. et al. A PDGFRbeta-based score predicts significant liver fibrosis in patients with chronic alcohol abuse, NAFLD and viral liver disease. EBioMedicine 43, 501\u2013512 (2019).","journal-title":"EBioMedicine"},{"key":"22636_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ki.2009.424","volume":"77","author":"P Mundel","year":"2010","unstructured":"Mundel, P. & Reiser, J. Proteinuria: An enzymatic disease of the podocyte?. Kidney Int. 77, 571\u2013580 (2010).","journal-title":"Kidney Int."},{"key":"22636_CR29","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1096\/fj.11-202994","volume":"26","author":"A Mima","year":"2012","unstructured":"Mima, A. et al. Glomerular VEGF resistance induced by PKCdelta\/SHP-1 activation and contribution to diabetic nephropathy. FASEB J. 26, 2963\u20132974 (2012).","journal-title":"FASEB J."},{"key":"22636_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240195","volume":"15","author":"MC Kim","year":"2020","unstructured":"Kim, M. C. et al. Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease. PLoS ONE 15, e0240195 (2020).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22636-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22636-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22636-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T10:21:07Z","timestamp":1666347667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22636-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22636"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22636-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"12 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M. received a speaker\u2019s honorarium from Otsuka, Kyowa Kirin, Mitsubishi Tanabe, Torii, Kowa, Sumitomo Pharma, Bayer, Eli Lilly, Astellas, and Boehringer Ingelheim. A.M. received research grants from Kyowa Kirin, Sumitomo Pharma, Otsuka, Torii, Daiichi-Sankyo, Mitsubishi Tanabe, Boehringer Ingelheim, and Eli Lilly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17630"}}